RP-HPLC Method Development and Validation for Simultaneous Estimation of Salicylic Acid and Tolnaftate in Bulk and Pharmaceutical Dosage Form
Misbah Sayyad, Archana Magdum*, Aaisha Shaikh, Pratiksha Bhadwankar,
Pratiksha Chaugule, Ansar Patel
Sant Gajanan Maharaj College of Pharmacy, Mahagaon, Site Chinchewadi 416503, Maharashtra, India.
*Corresponding Author E-mail: archurajmane@gmail.com
Abstract:
An efficient, exact, correct, and repeatable reverse-phase high-performance liquid chromatography (RP-HPLC) technique has been established and confirmed to determine salicylic acid (SA) and tolnaftate (TOL) in large and pharmaceutical dosage form. Separations were done by chromatography on an Inertsil ODS-3 C18 column (250 x 4.6mm, 5um), with a mobile phase of acetonitrile:0.1 per cent ortho-phosphoric acid (40:60, v/v) flow rate of 1.0 mL/min. Detection was done at 269nm by means of photodiode array (DAD) detector. SA and TOL time of retention were 3.700 and 4.980min, respectively, and the resolution was 5.70. The technique was confirmed according to the ICH Q2(R1) guidelines of system suitability, linearity, LOD, LOQ, and robustness. The correlation coefficients of 0.9999 and 0.9998 between the 16-80ug/mL (SA) and 2-10ug/mL (TOL) established linearity respectively. The LODs were 0.68ug/mL (SA) and 0.17ug/mL (TOL); the LOQs were 2.05ug/mL (SA) and 0.53 ug/mL (TOL). This method was sensitive to the step-wise changes in mobile phase composition (+-1% v/v), and detection wavelength (+-1nm) and in all cases, the resolution was at 5.21 and above. The method developed is easy, not expensive, and can be used during regular quality control of SA and TOL in combined topical pharmaceutical products.
KEYWORDS: RP-HPLC, Salicylic Acid, Tolnaftate, Method Validation, Pharmaceutical Quality Control.
INTRODUCTION:
The chemical structure of salicylic acid (Fig. 1) or 2-hydroxybenzoic acid (MW = 138.12g/mol) is a beta-hydroxy keratolytic agent, which is well-established and is commonly used in topical therapy of acne vulgaris, psoriasis, seborrheic dermatitis, dandruff, calluses and fungal infection superficially1,2. Salicylic acid also has concentration-dependent bacteriostatic and fungistatic activity, and thus, can also be used in topical therapeutic formulations as well as in proving the varied and depths of action of its keratolytic activity.
Fig. 1: Chemical structure of salicylic acid (2-Hydroxybenzoic acid; MW = 138.12 g/mol)
Fig. 2: Chemical structure of tolnaftate (O-2-naphthyl methyl(3-methylphenyl) thiocarbamate; MW = 307.41 g/mol)
Tolnaftate (Fig. 2) is an antifungal agent (made by synthesis) consisting of a thiocarbamate (O-2-naphthyl methyl(3-methylphenyl) thiocarbamate) (MW = 307.41g/mol), the chemical group with an antifungal effect that is directed at squalene epoxidase and thus interfering with the ergosterol biosynthesis of fungal cell membranes.3,6
Topical formulations of salicylic acid and tolnaftate as fixed-dose combinations have been commercially used in the treatment of superficial fungal infections complicated by hyperkeratosis due to the synergistic therapeutic effect of these two agents,3,6 which facilitate each other to increase their penetration and local activity (Salvatore et al., 2019). Although analytical procedures on individual salicylic acid7,8 and tolnaftate9,10 have been reported separately, the combined estimation of these drugs by RP-HPLC is rare in published literature, although the clinical relevance of this drug combination is clear. The current investigation was thus conducted to design and establish an easy, fast RP-HPLC technique to jointly measure salicylic acid and tolnaftate in bulk and pharmaceutical dosage forms as stipulated by ICH Q2(R1) guidelines.11-29
Materials and Methods:
Chemicals and Reagents:
Salicylic acid (purity 99.8 percent) and tolnaftate (purity 99.5 percent) working standards were purchased at Sigma- Aldrich, Mumbai, India. Merck Life Science Pvt. Ltd, Mumbai procured acetonitrile and methanol that were of HPLC grade. Ortho-phosphoric acid (AR grade) was acquired under S.D. Fine Chemicals, Mumbai. The study used milli-q purified water (Millipore, USA).
Instrumentation:
An Agilent 1200 series HPLC system, comprising of quaternary pump, auto-sampler, thermostatted column compartment and diode array detector (DAD) were used in chromatographic analyses and operated using OpenLAB CDS ChemStation software (RSITC Instrument 1). Separating was done on an Inertsil ODS-3 C18 column (250 x 4.6mm, 5um; GL Sciences, Japan). Sample preparation was done using a digital ultrasonic bath and 0.45um PVDF membrane filtration system. Any weighing done was on calibrated analytical balance.
Optimized Chromatographic Conditions:
Mobile phase acetonitrile: 0.1% Ortho-phosphoric acid (40:60, v/v); flow rate: 1.0mL/min; column temperature: 30 deg C; injection volume: 20uL; detection wavelength: 269nm (DAD); run time: 8.0minutes. Mobile phase was made daily, filtered using 0.45um nylon membrane and then total 15 minutes of ultrasonic de-gassing taking place.11
Preparation of Standard Stock Solutions:
Weighed 80mg of salicylic acid and 10mg of tolnaftate were found in 100mL volumetric flasks and dissolved in methanol with sonication within 10minutes and diluted to 100mL with mobile phase, producing stock solutions of 800ug/mL (SA) and 100ug/mL (TOL). Solutions were kept at 4degC in the absence of light and used in 7 days.
Preparation of Working Solutions for Linearity:
The stock solutions were diluted serially using mobile phase: 16+2, 32+4, 48+6, 64+8 and 80+10ug/mL SA and TOL respectively to obtain 5 concentration levels of the working solutions and proceed to the next stage of the study. All the concentration levels were prepared in duplicate and filtered using a 0.45um PVDF syringe filter just before injection.
Method Validation:
The method was validated as per ICH Q2(R1) guidline11. for system suitability, linearity, limit of detection (LOD), limit of quantitation (LOQ), and robustness.
System Suitability:
The standard working solution (80+10µg/mL) was injected and parameters including retention time, theoretical plate count (N), tailing factor (T), and resolution (Rs) were evaluated against ICH-specified acceptance criteria.
Linearity:
Duplicate injections were made at five concentration levels. Peak area versus concentration was plotted and subjected to least-squares linear regression to obtain the calibration equation and correlation coefficient.11
LOD and LOQ:
Calculated from calibration curve statistics using LOD = 3.3σ/S and LOQ = 10σ/S, where σ is the standard deviation of the y-intercept and S is the slope of the regression line.11
Robustness:
Deliberate small variations were introduced in the mobile phase organic modifier proportion (±1% v/v: 39:61 and 41:59) and detection wavelength (±1nm: 268nm and 270nm) to assess the impact on chromatographic performance.11
Results and Discussion:
Optimization of Chromatographic Conditions:
The development of the method started by the systematic analysis of mobile phase compositions, pH modifiers, and column temperatures that allowed obtaining sufficient separation of salicylic acid and tolnaftate. Mobile phases containing methanol had large and asymmetric tolnaftate peaks due to its medium lipophilicity. Systems with aqueous acetone gave significantly better peak shape, column efficiency and run time. Introduction of 0.1% ortho-phosphoric acid inhibited the ionization of the carboxylic acid group of salicylic acid (pKa [?] 3.0) at the operating pH (~2.5), giving a sharp and symmetrical peak. Systematic optimization studies then identified a mobile phase of acetonitrile: 0.1% ortho-phosphoric acid (40:60, v/v) at 1.0mL/min using UV detection at 269nm on an Inertsil ODS-3 C18 column as a good one to achieve a good resolution (Rs = 5.70) and complete separation in 8 min.
Standard Chromatogram and System Suitability:
The chromatogram (Fig. 3) obtained under the optimum conditions reflects two sharp and symmetrical and separated baseline peaks of salicylic acid and tolnaftate with retention time of 3.700 and 4.980min, respectively. The summary of system suitability parameters is presented in Table 1. The plate counts of 5621/SA and 6270/TOL are significantly greater than the ICH minimum of 2000 plates per column, and it proves high column efficiency. Tailing factors of 0.91 and 0.92 are substantially less than 2.0 which confirms that there was good symmetry in the peaks. The resolution of 5.70 is way above 2.0 minimum, which makes sure that there is 100 percent separation of both analytes between the bases. The replicate injection percentage RSD of the peak areas was 0.030% (SA) and 0.381% (TOL) which falls within the acceptance threshold of 2.0%.
Fig. 3: Standard chromatogram of salicylic acid (Rt = 3.700 min) and tolnaftate (Rt = 4.980 min) under optimized conditions. SA: 80 µg/mL, TOL: 10 µg/mL; ACN:0.1% OPA (40:60, v/v); 1.0 mL/min; 269 nm. Data file ST000026, RSITC Instrument 1, 30-01-2026.
Table 1: System suitability parameters for salicylic acid and tolnaftate
|
Parameter |
Salicylic Acid (80 µg/mL) |
Tolnaftate (10 µg/mL) |
Acceptance Criterion |
Compliance |
|
Retention time (min) |
3.700 |
4.980 |
— |
Pass |
|
Theoretical plate count (N) |
5621 |
6270 |
> 2000 |
Pass |
|
Tailing factor (T) |
0.91 |
0.92 |
< 2.0 |
Pass |
|
Resolution (Rs) |
— |
5.70 |
> 2.0 |
Pass |
|
%RSD of peak area
|
0.030 |
0.381 |
< 2.0 |
Pass |
N, tailing, and Rt from linearity and repeatability injections (data files ST000026, ST000046–ST000047); %RSD from duplicate repeatability injections.
Linearity:
The ranges of concentration that were studied in linearity were 16-80ug/mL on the SA concentration and 2-10 ug/mL on the TOL concentration with five levels and replicas of each level as shown in Table 2. Fig. 6 provides the overlay chromatograms of the five levels of linearity. The Figs. 4 and 5 show calibration curves built based on the data of the area of the peaks versus the concentration. There was a good linear correlation, with equations of regression in the form of y = 33.03x + 9.27 (R2 = 0.9999) and y = 111.82x + 11.16 (R2 = 0.9998) as Stores and Time of Length of Stay respectively. The correlation coefficients of near unity verify the uniformity of detector response proportion of the entire working range, which is akin to that of Beer-Lambert linearity.11 Repeat injection injections at both levels had a smaller percent (less than 0.7 percent) of the RSD of SA and TOL.
|
Fig. 4: Calibration curve — Salicylic acid (y = 33.03x + 9.27; R² = 0.9999; 16–80 µg/mL) 5 levels, duplicate injections; data from file. |
Fig. 5: Calibration curve — Tolnaftate (y = 111.82x + 11.16; R² = 0.9998; 2–10 µg/mL) 5 levels, duplicate injections; data from file. |
Fig. 6: Overlaid linearity chromatograms — five concentration levels (C1: 16+2, C2: 32+4, C3: 48+6, C4: 64+8, C5: 80+10 µg/mL for SA+TOL). Data files ST000017–ST000026, RSITC Instrument 1, 30-01-2026.
Table 2: Linearity data for salicylic acid and tolnaftate — mean of duplicate injections from file
|
SA Conc. (µg/mL) |
SA Mean Peak Area (mAU·s) |
TOL Conc. (µg/mL) |
TOL Mean Peak Area (mAU·s) |
|
16 |
544.86 |
2 |
235.72 |
|
32 |
1061.36 |
4 |
453.27 |
|
48 |
1588.88 |
6 |
689.87 |
|
64 |
2122.42 |
8 |
901.74 |
|
80 |
2657.08 |
10 |
1129.65 |
|
Regression equation |
y = 33.03x + 9.27 |
Regression equation |
y = 111.82x + 11.16 |
|
Correlation coefficient (R²) |
0.9999 |
Correlation coefficient (R²) |
0.9998 |
SA = Salicylic Acid; TOL = Tolnaftate. Source data files: ST000017–ST000026, RSITC Instrument 1, 30-01-2026.
Limit of Detection and Limit of Quantitation:
The standard of calibration curve was used to determine LOD and LOQ, with LOD = 3.3s/S and LOQ = 10s/S (s is the standard deviation of the y-intercept of the calibration curve with S being the slope). LOD =0.68 ug/mL and LOQ=2.05 ug/mL of salicylic acid and tolnaftate, respectively. These values are attesting to high analytical sensitivity especially on the lower concentration level of tolnaftate in the integrated formulation. Both the analytes could be detected and quantified far below the lower limits of the working range.
Repeatability:
The test was repeated at 269nm and was based on a replicate injection of the standard solution (80+10ug/mL) in order to determine repeatability. Fig. 7 shows the representative repeatability chromatograms of the two injections that are provided in the data files. The highest percentage of peak area relative standard deviation was 0.030% in the case of SA and 0.381% in the case of TOL which is well below the ICH acceptance limit of 2.0%, which demonstrates an excellent injection to injection reproducibility under the optimum conditions.
Fig. 7: Repeatability chromatograms — replicate injections of standard solution (SA: 80 µg/mL, TOL: 10 µg/mL; 269nm). %RSD: SA = 0.030%, TOL = 0.381%. Data files ST000046–ST000047, RSITC Instrument 1, 30-01-2026.
Robustness:
The evaluation of robustness was conducted by the intentional changes in the ratio of the mobile phase organic modifier (+-1 percent: 39:61, 41:59 v/v) and the detection wavelength (+-1nm: 268, 270nm). Figs. 8 and 9, respectively, show the robustness chromatograms with respect to mobile phase variation and wavelength variation, respectively. All the data are tabulated in Table 3. All six of the tested conditions provided full baseline resolution between salicylic acid and tolnaftate (Rs range: 5.21-5.82), tailoring factors were below 1.0, and theoretical plate counts were over 5000. Changes in the retention time with phase transition in the organic phase were predictable and in line with the retention theory of chromatography. The variation in wavelength of +-1 nm caused slight changes in the area of the peaks (as is anticipated by the nature of UV absorption at the edge of absorption maximum) without altering the quality of resolution and separation. Such findings verify that the technique is strong and capable of withstanding small accidental variations in the operation parameters that are experienced when carrying out the analysis routinely.
Fig. 8: Robustness study — mobile phase composition variation: (a) ACN:0.1% OPA 39:61 v/v, Rs = 5.82; (b) 40:60 v/v nominal, Rs = 5.70; (c) 41:59 v/v, Rs = 5.23. Data files ST000009–ST000012, RSITC Instrument 1, 31-01-2026.
Fig. 9: Robustness study — detection wavelength variation: (a) 268 nm (DAD Ch.A), Rs = 5.51; (b) 269 nm nominal, Rs = 5.70; (c) 270 nm (DAD Ch.B), Rs = 5.51. Data files ST000006–ST000007, RSITC Instrument 1, 31-01-2026.
Table 3: Robustness results for salicylic acid and tolnaftate
|
Parameter |
Condition |
SA Rt (min) |
SA Area (mAU·s) |
TOL Rt (min) |
TOL Area (mAU·s) |
Rs |
|
Mobile phase (ACN:0.1% OPA) |
Less: 39:61 v/v |
3.822 |
1530.9 |
5.281 |
649.9 |
5.82 |
|
|
Nominal: 40:60 |
3.700 |
2658.0 |
4.980 |
1130.6 |
5.70 |
|
|
More: 41:59 v/v |
3.692 |
1541.8 |
4.928 |
647.9 |
5.23 |
|
Detection wavelength |
268 nm (DAD Ch.A) |
3.754 |
1639.6 |
5.098 |
621.8 |
5.51 |
|
|
269 nm (nominal) |
3.700 |
2658.0 |
4.980 |
1130.6 |
5.70 |
|
|
270 nm (DAD Ch.B) |
3.754 |
1436.3 |
5.098 |
678.5 |
5.51 |
All conditions: Rs > 2.0 (Pass); tailing factor < 1.0; plate count > 5000. Source: ST000006–ST000012, RSITC Instrument 1, 31-01-2026.
Conclusion:
An RP-HPLC procedure with acetonitrile:0.1% ortho-phosphoric acid (40:60, v/v) as mobile phase, a UV detector at 269nm and Inertsil ODS-3 C18 column have been established and validated as a simple, sensitive and reproducible method that can simultaneously estimate salicylic acid and tolnaftate. The approach has good baseline resolution (Rs = 5.70) and short retention times (SA 3.700min, TOL 4.980min) in a total of 8 minutes of run time. Over 16-80 ug/mL (SA) and 2-10 ug/mL (TOL), it was established that the linearity was confirmed and the correlation coefficients were 0.9999 and 0.9998, respectively. According to LOD and LOQ, tolnaftate has high sensitivity. The procedure was found to be highly robust to systematic changes in mobile phase composition (+-1%) and detection wavelength (+-1nm), and resolution was found to exceed 5.21 in all cases. It is also economical in terms of cost, can be easily transferred to routine quality control laboratories, and can be used concomitantly in the analysis of salicylic acid as well as tolnaftate in combined drugs that are used as topical agents.
References:
1. Tosti A, Piraccini BM. Salicylic acid. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Philadelphia: Elsevier Saunders; 2013:437–442.
2. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. J Am Acad Dermatol. 2006; 54(5): 818–823.
3. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008; 166(5–6): 353–367.
4. Degreef H. Clinical forms of dermatophytosis (tinea). Mycopathologia. 2008; 166(5–6): 257–265.
5. Hay RJ, Ashbee HR. Mycology. In: Burns T, ed. Rook's Textbook of Dermatology. 8th ed. Oxford: Wiley-Blackwell. 2010; 36: 1–101.
6. Roberts DT, Evans EG, Allen BR. Fungal Infection of the Skin and Nail. London: Martin Dunitz; 2003:14–45.
7. Reddy BP, Murthy VN, Rajesh B, Venkateswarlu A. Development and validation of RP-HPLC method for simultaneous estimation of salicylic acid and betamethasone valerate in topical formulation. Int J Pharm Pharm Sci. 2010; 2(3): 115–119.
8. Manjunath DP, Ramesh A, Harikumar SL. RP-HPLC method for simultaneous estimation of clobetasol propionate and salicylic acid in topical dosage form. Int J Pharm Res. 2011; 3(1): 70–74.
9. Gandhi S, Mehta P, Patel V, Patel S. Development and validation of UV spectrophotometric and RP-HPLC methods for determination of tolnaftate in pharmaceutical formulations. J Chem Pharm Res. 2012; 4(5): 2541–2546.
10. Khan IM, Nanda RK. RP-HPLC method for the quantitative determination of tolnaftate in topical dosage form. Int J Pharm Technol. 2013; 5(3): 5918–5926.
11. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology Q2(R1). Geneva: ICH; November 2005.
12. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A(R2). Geneva: ICH; November 2003.
13. U.S. Food and Drug Administration. Guidance for Industry, Analytical Procedures and Methods Validation for Drugs and Biologics. Silver Spring, MD: FDA; 2015.
14. United States Pharmacopoeia. <1225> Validation of Compendial Procedures. USP 40–NF 35. Rockville, MD: United States Pharmacopeial Convention; 2017.
15. Raveendra Babu G, Srinivasa Rao J, Suresh Kumar K, Jayachandra Reddy P. Stability Indicating Liquid Chromatographic Method for Aripiprazole. Asian J Pharm Ana. 2011; 1(1): 3–7.
16. Gupta A, Yadav JS, Rawat S, Gandhi M. Method Development and Hydrolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS. Asian J Pharm Ana. 2011; 1(1): 14–18.
17. Satyanarayana L, Naidu SV, Narasimha Rao M, Ayyanna C, Kumar A. The Estimation of Raltigravir in Tablet Dosage Form by RP-HPLC. Asian J Pharm Ana. 2011; 1(3): 56–58.
18. Haque MA, Shahriar M, Parvin MN, Islam SMA. Validated RP-HPLC Method for Estimation of Ranitidine Hydrochloride, Domperidone and Naproxen in Solid Dosage Form. Asian J Pharm Ana. 2011; 1(3): 59–63.
19. Afroz A, Haque T, Talukder MMU, Islam SMA. Spectrophotometric Estimation of Rosuvastatin Calcium and Glimepiride in Tablet Dosage Form. Asian J Pharm Ana. 2011; 1(4): 74–78.
20. Sebaiy MM, El-Shanawany AA, El-Adl SM, Abdel-Aziz LM, Hashem HA. Rapid RP-HPLC Method for Simultaneous Estimation of Norfloxacin and Tinidazole in Tablet Dosage Form. Asian J Pharm Ana. 2011; 1(4): 79–84.
21. Thenmozhi A, Sridharan D, Veeramani S, Palanivelu M. An RP-HPLC Method for the Estimation of Dexibuprofen in Pharmaceutical Tablet Dosage Form. Asian J Pharm Ana. 2011; 1(4): 98–99.
22. Satyanarayana L, Naidu SV, Narasimha Rao M, Suma Latha R. The Estimation of Nilotinib in Capsule Dosage Form by RP-HPLC. Asian J Pharm Ana. 2011; 1(4): 100–102.
23. Chowdhury SR, Maleque M, Shihan MH. Development and Validation of a Simple RP-HPLC Method for Determination of Caffeine in Pharmaceutical Dosage Forms. Asian J Pharm Ana. 2012; 2(1): 1–4.
24. Janaki Pathi P, Appala Raju N. The Estimation of Cefquinome Sulphate in Suspension Form by RP-HPLC. Asian J Pharm Ana. 2012; 2(2): 33–35.
25. Janaki Pathi P, Appala Raju N. The Estimation of Epalrestat in Tablet Dosage Form by RP-HPLC. Asian J Pharm Ana. 2012; 2(2): 49–51.
26. Analytical Method Development and Method Validation for the Simultaneous Estimation of Metformin Hydrochloride and Pioglitazone Hydrochloride in Tablet Dosage Form by RP-HPLC. Asian J Pharm Ana. 2012; 2(3): 85–89.
27. Janaki Pathi P, Appala Raju N, Parvathalu G. The Estimation of Sapropterin Dihydrochloride in Tablet Dosage Form by RP-HPLC. Asian J Pharm Ana. 2012; 2(4): 110–113.
28. Revathi R, Venkata Naga Suresh P, Koteswara Rao M, Ethiraj T, Rajarajan S. Development and Validation of RP-HPLC Method for Content Analysis of Didanosine in Dosage Form. Asian J Pharm Ana. 2012; 2(4): 118–121.
29. Satyanarayana L, Naidu SV, Narasimha Rao M, Ayyanna C, Kumar A. The Estimation of Raltigravir in Tablet Dosage Form by RP-HPLC. Asian J Pharm Ana. 2011; 1(3): 56–58.
|
Received on 15.06.2026 Revised on 29.07.2026 Accepted on 04.09.2026 Published on 19.10.2026 Available online from October 31, 2026 Research J. Science and Tech. 2026; 18(4):339-345. DOI: 10.52711/2349-2988.2026.00047
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|